| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA5196004
Max Phase: Preclinical
Molecular Formula: C29H25FN6O2
Molecular Weight: 508.56
Associated Items:
Representations
Canonical SMILES: O=C(NCCNc1cc(-c2cn(-c3ccccc3)nc2-c2cccc(O)c2)ccn1)Nc1ccc(F)cc1
Standard InChI: InChI=1S/C29H25FN6O2/c30-22-9-11-23(12-10-22)34-29(38)33-16-15-32-27-18-20(13-14-31-27)26-19-36(24-6-2-1-3-7-24)35-28(26)21-5-4-8-25(37)17-21/h1-14,17-19,37H,15-16H2,(H,31,32)(H2,33,34,38)
Standard InChI Key: DOPVRNNEAOBWGJ-UHFFFAOYSA-N
Associated Targets(Human)
c-Jun N-terminal kinase 3 3396 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 508.56 | Molecular Weight (Monoisotopic): 508.2023 | AlogP: 5.68 | #Rotatable Bonds: 8 |
| Polar Surface Area: 104.10 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 4 |
| #RO5 Violations: 2 | HBA (Lipinski): 8 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 2 |
| CX Acidic pKa: 9.55 | CX Basic pKa: 5.75 | CX LogP: 5.36 | CX LogD: 5.35 |
| Aromatic Rings: 5 | Heavy Atoms: 38 | QED Weighted: 0.20 | Np Likeness Score: -1.52 |
References
| 1. Abu Rabah RR, Sebastian A, Vunnam S, Sultan S, Tarazi H, Anbar HS, Shehata MK, Zaraei SO, Elgendy SM, Al Shamma SA, Omar HA, Al-Tel TH, El-Gamal MI.. (2022) Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors., 69 [PMID:35764033] [10.1016/j.bmc.2022.116894] |
Source
Source(1):